A Phase 3 interventional study of placebo and telmisartan + HCTZ in Hypertension, sponsored by Boehringer Ingelheim. Completed at 17 sites in Japan. Open to participants aged 20 Years to 100 Years. Per ClinicalTrials.gov, last updated 2016-03-28.
Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 187 studies testing amlodipine in Hypertension — 6 open to participants now, 8 under way, 2 of them phase 3. Amlodipine · Hypertension.
Among the 187 studies testing amlodipine in Hypertension, this one is the 112th largest by enrollment of the 186 interventional ones that give a count, is one of 7 that started in 2013, is one of 69 in phase 3, and was the 113th registered.
6,122 studies on the registry are indexed under Hypertension; 913 are open to participants now.
Browse Hypertension studies →6 of the 187 studies testing amlodipine in Hypertension are open now, in 4 countries. Recruiting first, the newest first:
National Medical Research Center for Therapy and Preventive Medicine · Sites in Russia
Ages 50–70
Shenzhen Ausa Pharmed Co.,Ltd · Sites in China
Ages 45–74
Shenzhen Ausa Pharmed Co.,Ltd · Sites in China
Ages 45–74
Hyundai Pharm · Sites in Korea, Republic of
Ages 19+
Zentiva, k.s.
Ages 50–79 · Women only
By country, each count listing its studies:
Amlodipine: first FDA approval 1992 (NORVASC), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 563 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (36%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 20 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
187 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 9 · Phase 3 71 · Phase 4 80
First in 1999; this study’s year is marked. 7 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 132 is above the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 180 across the 186 interventional studies. Of the 156 that completed or were terminated, 53 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
120 of 187 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
122 studies in Hypertension by Boehringer Ingelheim: 1 open now, 1 under way, 1 of them phase 3. Of 120 finished, 41 (34%) have results posted.
Among the 122 studies in Hypertension by Boehringer Ingelheim, this one is the 56th largest by enrollment of the 74 interventional ones that give a count, is one of 2 that started in 2013, is one of 43 in phase 3, and was the 67th registered.
Boehringer Ingelheim’s Hypertension studies by the year they started, since 1995.
None of the studies under way reaches primary completion within a year.
Among the 187 studies testing amlodipine in Hypertension, from their registry updates:
Among Boehringer Ingelheim’s 122 in Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multi-centre, randomised, double-blind, active-controlled, parallel-group comparative trial to compare the fixed dose combination (FDC) of telmisartan 80 mg + hydrochlorothiazide 12.5 mg and amlodipine 5 mg (T80/A5/H12.5 mg) to telmisartan 80 mg+ hydrochlorothiazide 12.5 mg (T80/H12.5 mg) in blood pressure lowering effect at week 8, the end of the double-blind period in essential hypertensive patients who fail to respond adequately to telmisartan 80 mg+ hydrochlorothiazide 12.5 mg.
Patients are assigned to one of the two groups after a 6-week open-label run-in period taking T80/H12.5 mg.
In addition the long-term safety of telmisartan 80 mg+ amlodipine 5 mg+ hydrochlorothiazide 12.5 mg will be evaluated in a 52-week extension period.
In the 52-week open label extension period patients who are assigned to the T80/A5/H12.5 mg group continue the T80/A5/H12.5 mg therapy, and patients who are assigned to the T80/ /H12.5 mg group change to the T80/A5/H12.5 mg therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
telmisartan 80 mg + hydrochlorothiazide (HCTZ) 12.5 mg fixed dose combination (FDC) and amlodipine 5 mg capsule (after the 8-week double-blind period, patients will continue the 52-week open label extension period taking 1 telmisartan 80 mg and hydrochlorothiazide 12.5 FDC tablet and 1 amlodipine 5 mg tablet)
Drug: telmisartan + HCTZ · Drug: amlodipine
telmisartan 80 mg + HCTZ FDC tablet and placebo matching amlodipine 5 mg capsule (after the 8-week double-blind period, patients will continue the 52-week open label extension period taking 1 telmisartan 80 mg and hydrochlorothiazide 12.5 FDC tablet and 1 amlodipine 5 mg tablet)
Drug: placebo · Drug: telmisartan + HCTZ
placebo matching amlodipine capsule
Drug pages: Telmisartan · Hydrochlorothiazide
FDC tablet
Drug pages: Telmisartan · Hydrochlorothiazide
FDC tablet
capsule
Change From Baseline in Mean Seated DBP at Trough After 8 Weeks of the Double-blind Period.
Change from baseline in mean seated diastolic blood pressure (DBP) at trough (24-hour post dosing) after 8 weeks of the double-blind period. The results are presented as 'change' rather than 'reduction' i.e., reductions are expressed with negative values'. The 'adjusted mean' is shown as 'mean'.
Time frame: baseline and 8 weeks
Change From Baseline in Mean Seated SBP at Trough After 8 Weeks of the Double-blind Period.
Change from baseline in mean seated systolic blood pressure (SBP) at trough after 8 weeks of the double-blind period. The results are presented as 'change' rather than 'reduction' i.e., reductions are expressed with negative values'. The 'adjusted mean' is shown as 'mean'.
Time frame: baseline and 8 weeks
The Percentage of Patients With DBP<90 mmHg and SBP<140 mmHg Blood Pressure at Trough After 8 Weeks of Double-blind Period.
The percentage of patients with DBP\<90 mmHg and SBP\<140 mmHg as seated blood pressure at trough after 8 weeks of the double-blind period. The results are presented as 'change' rather than 'reduction' i.e., reductions are expressed with negative values'. The 'adjusted mean' is shown as 'mean'.
Time frame: Double-blind and 8 weeks
The Number of Patients With DBP<90 mmHg and SBP<140 mmHg Blood Pressure at Trough After 52 Weeks of Extension Period.
The number of patients with DBP\<90 mmHg and SBP\<140 mmHg as seated blood pressure at trough after 52 weeks of the extension period. Note, week 52 of the extension period corresponds to 60 weeks after the reference baseline. The results are presented as 'change' rather than 'reduction' i.e., reductions are expressed with negative values'. The 'adjusted mean' is shown as 'mean'.
Time frame: Reference baseline (week 0) and week 60 (end of extension period)
Change From Baseline in Mean DBP Pressure at Trough After 52 Weeks of the Extension Period.
Change from baseline in mean seated diastolic blood pressure at trough after 52 weeks of the extension period. Note, week 52 of the extension period corresponds to 60 weeks after the reference baseline. The results are presented as 'change' rather than 'reduction' i.e., reductions are expressed with negative values'. The 'adjusted mean' is shown as 'mean'.
Time frame: Reference baseline (week 0) and week 60 (end of extension period)
Change From Baseline in Mean Seated SBP at Trough After 52 Weeks of the Extension Period.
Change from baseline in mean seated systolic blood pressure at trough after 52 weeks of the extension period. Note, week 52 of the extension period corresponds to 60 weeks after the reference baseline. The results are presented as 'change' rather than 'reduction' i.e., reductions are expressed with negative values'. The 'adjusted mean' is shown as 'mean'.
Time frame: Reference baseline (week 0) and week 60 (end of extension period)
Of the 239 enrolled patients, 205 patients were entered in the run-in period and 132 were randomized. The remaining 107 patients were withdrawn from the trial before the randomization.
| Milestone | Telmisartan + HCTZ + Amlodipine | Telmisartan + HCTZ + Placebo |
|---|---|---|
| Started | 68 | 64 |
| Completed | 65 | 61 |
| Not completed | 3 | 3 |
| Withdrew: Adverse event | 1 | 2 |
| Withdrew: Consent withdrawn not due to aes | 1 | 1 |
| Withdrew: Personal reason | 1 | 0 |
| Milestone | Telmisartan + HCTZ + Amlodipine | Telmisartan + HCTZ + Placebo |
|---|---|---|
| Started | 65 | 61 |
| Completed | 61 | 58 |
| Not completed | 4 | 3 |
| Withdrew: Adverse event | 3 | 0 |
| Withdrew: Consent withdrawn not due to aes | 0 | 2 |
| Withdrew: Personal reason | 1 | 1 |
Change from baseline in mean seated diastolic blood pressure (DBP) at trough (24-hour post dosing) after 8 weeks of the double-blind period. The results are presented as 'change' rather than 'reduction' i.e., reductions are expressed with negative values'. The 'adjusted mean' is shown as 'mean'.
| mmHg | Telmisartan + HCTZ + Amlodipine | Telmisartan + HCTZ + Placebo |
|---|---|---|
| Change From Baseline in Mean Seated DBP at Trough After 8 Weeks of the Double-blind Period. | -8.8 ± 0.8 | -1.3 ± 0.8 |
Change from baseline in mean seated systolic blood pressure (SBP) at trough after 8 weeks of the double-blind period. The results are presented as 'change' rather than 'reduction' i.e., reductions are expressed with negative values'. The 'adjusted mean' is shown as 'mean'.
| mmHg | Telmisartan + HCTZ + Amlodipine | Telmisartan + HCTZ + Placebo |
|---|---|---|
| Change From Baseline in Mean Seated SBP at Trough After 8 Weeks of the Double-blind Period. | -10.6 ± 1.4 | -2.1 ± 1.5 |
The percentage of patients with DBP\<90 mmHg and SBP\<140 mmHg as seated blood pressure at trough after 8 weeks of the double-blind period. The results are presented as 'change' rather than 'reduction' i.e., reductions are expressed with negative values'. The 'adjusted mean' is shown as 'mean'.
| Participants | Telmisartan + HCTZ + Amlodipine | Telmisartan + HCTZ + Placebo |
|---|---|---|
| The Percentage of Patients With DBP<90 mmHg and SBP<140 mmHg Blood Pressure at Trough After 8 Weeks of Double-blind Period. | 44.8 (32.6 to 57.4) | 21.9 (12.5 to 34.0) |
The number of patients with DBP\<90 mmHg and SBP\<140 mmHg as seated blood pressure at trough after 52 weeks of the extension period. Note, week 52 of the extension period corresponds to 60 weeks after the reference baseline. The results are presented as 'change' rather than 'reduction' i.e., reductions are expressed with negative values'. The 'adjusted mean' is shown as 'mean'.
| Participants | Telmisartan + HCTZ + Amlodipine | Telmisartan + HCTZ + Placebo |
|---|---|---|
| Yes | 41 (32.6 to 57.4) | 33 (12.5 to 34.0) |
| No | 24 | 28 |
Change from baseline in mean seated diastolic blood pressure at trough after 52 weeks of the extension period. Note, week 52 of the extension period corresponds to 60 weeks after the reference baseline. The results are presented as 'change' rather than 'reduction' i.e., reductions are expressed with negative values'. The 'adjusted mean' is shown as 'mean'.
| mmHg | Telmisartan + HCTZ + Amlodipine + Ext | Telmisartan + HCTZ + Placebo + Ext |
|---|---|---|
| Mean | -11.4 ± 1.0 | -10.0 ± 1.0 |
| Adjusted mean | -10.9 ± 1.0 | -10.5 ± 1.0 |
Change from baseline in mean seated systolic blood pressure at trough after 52 weeks of the extension period. Note, week 52 of the extension period corresponds to 60 weeks after the reference baseline. The results are presented as 'change' rather than 'reduction' i.e., reductions are expressed with negative values'. The 'adjusted mean' is shown as 'mean'.
| mmHg | Telmisartan + HCTZ + Amlodipine + Ext | Telmisartan + HCTZ + Placebo + Ext |
|---|---|---|
| Mean | -14.8 ± 1.6 | -14.3 ± 1.6 |
| Adjusted mean | -13.6 ± 1.3 | -15.9 ± 1.4 |
Collected over Up to 60 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Telmisartan + HCTZ + Amlodipine - Double Blind Period | — | 0/68 (0%) | 7/68 (10.3%) |
| Telmisartan + HCTZ + Placebo - Double Blind Period | — | 0/64 (0%) | 6/64 (9.4%) |
| Telmisartan + HCTZ + Amlodipine - Extension Period | — | 2/65 (3.1%) | 26/65 (40%) |
| Telmisartan + HCTZ + Placebo - Extension Period | — | 2/61 (3.3%) | 16/61 (26.2%) |
| Event | Telmisartan + HCTZ + Amlodipine - Double Blind Period | Telmisartan + HCTZ + Placebo - Double Blind Period | Telmisartan + HCTZ + Amlodipine - Extension Period | Telmisartan + HCTZ + Placebo - Extension Period |
|---|---|---|---|---|
| Large intestine polypGastrointestinal disorders | 0/68 | 0/64 | 0/65 | 1/61 |
| Lacunar infarctionNervous system disorders | 0/68 | 0/64 | 0/65 | 1/61 |
| Rib fractureInjury, poisoning and procedural complications | 0/68 | 0/64 | 1/65 | 0/61 |
| Spinal fractureInjury, poisoning and procedural complications | 0/68 | 0/64 | 1/65 | 0/61 |
| HaemothoraxRespiratory, thoracic and mediastinal disorders | 0/68 | 0/64 | 1/65 | 0/61 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/68 | 0/64 | 1/65 | 0/61 |
| Deep vein thrombosisVascular disorders | 0/68 | 0/64 | 1/65 | 0/61 |
| Event | Telmisartan + HCTZ + Amlodipine - Double Blind Period | Telmisartan + HCTZ + Placebo - Double Blind Period | Telmisartan + HCTZ + Amlodipine - Extension Period | Telmisartan + HCTZ + Placebo - Extension Period |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 6/68 | 6/64 | 23/65 | 16/61 |
| Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders | 2/68 | 1/64 | 4/65 | 1/61 |
Treated set (TS) was defined as a collection of patients i) randomised to the double-blind period; ii) taking at least 1 dose of either T80/A5/H12.5 mg or T80/H12.5 mg during the double-blind period.
| Age, Continuous(Years) | Telmisartan + HCTZ + Amlodipine | Telmisartan + HCTZ + Placebo | Total |
|---|---|---|---|
| Mean | 56.1 ± 10.2 | 54.4 ± 7.9 | 55.2 ± 9.2 |
| Sex: Female, Male(Participants) | Telmisartan + HCTZ + Amlodipine | Telmisartan + HCTZ + Placebo | Total |
|---|---|---|---|
| Female | 13 | 15 | 28 |
| Male | 55 | 49 | 104 |
The record gives a start of Jul 2013, a primary completion of Jan 2015 and a completion of Jan 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2016, 1 year 2 months after primary completion. A results delay was requested in Jun 2014.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Amlodipine